Empagliflozin in Heart Failure Dialysis Patients
NCT05967156 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2025-06-06
Summary
Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.
Conditions
- Heart Failure
- Hemodialysis
Interventions
- DRUG
-
Empagliflozin10Mg Tab
10 mg daily
Sponsors & Collaborators
-
Shahid Beheshti University of Medical Sciences
lead OTHER
Principal Investigators
-
Dalili · SMBU
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-06-01
- Primary Completion
- 2025-06-01
- Completion
- 2025-06-03
Countries
- Iran
Study Locations
More Related Trials
-
The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients
NCT06365541 ·Status: RECRUITING ·Phase: PHASE4
-
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
NCT06483074 ·Status: RECRUITING ·Phase: PHASE2
-
The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
NCT05360615 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
NCT03485092 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure
NCT05141552 ·Status: UNKNOWN ·Phase: NA
-
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
NCT04961931 ·Status: UNKNOWN ·Phase: NA
-
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
NCT05715814 ·Status: RECRUITING ·Phase: PHASE3
-
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
NCT05392764 ·Status: RECRUITING ·Phase: PHASE3
-
Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation
NCT04918407 ·Status: COMPLETED ·Phase: NA
-
Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
NCT06706791 ·Status: RECRUITING ·Phase: PHASE4
-
Empaglifozin in Early Diabetic Kidney Disease
NCT03173963 ·Status: WITHDRAWN ·Phase: PHASE3
-
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
NCT03594110 ·Status: COMPLETED ·Phase: PHASE3
-
Empagliflozin and Renal Oxygenation in Healthy Volunteers
NCT03093103 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
NCT05373004 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI
NCT03591991 ·Status: UNKNOWN ·Phase: NA
-
SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency
NCT05737186 ·Status: TERMINATED ·Phase: PHASE4
-
SGLT2 Inhibition in Hemodialysis
NCT05179668 ·Status: COMPLETED ·Phase: PHASE2
-
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
NCT05321706 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
NCT06507657 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes
NCT03132181 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
NCT06260059 ·Status: RECRUITING ·Phase: PHASE4
-
The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
NCT05042973 ·Status: COMPLETED ·Phase: PHASE2
-
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
NCT07175051 ·Status: RECRUITING ·Phase: PHASE2
-
Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease
NCT05196347 ·Status: COMPLETED ·Phase: PHASE3
-
Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina
NCT04143321 ·Status: COMPLETED ·Phase: PHASE4